Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Nuclear Medicine
Published in: Annals of Nuclear Medicine 7/2021

01-07-2021 | Radiation Protection | Special Article

Manual on the proper use of sodium astatide ([211At]NaAt) injections in clinical trials for targeted alpha therapy (1st edition)

Authors: Tadashi Watabe, Makoto Hosono, Seigo Kinuya, Takahiro Yamada, Sachiko Yanagida, Masao Namba, Yoshihide Nakamura

Published in: Annals of Nuclear Medicine | Issue 7/2021

Login to get access

Abstract

We present the guideline for use of [211At] sodium astatide (NaAt) for targeted alpha therapy in clinical trials on the basis of radiation safety issues in Japan. This guideline was prepared by a study supported by the Ministry of Health, Labour, and Welfare, and approved by the Japanese Society of Nuclear Medicine on 8th Feb, 2021. The study showed that patients receiving [211At]NaAt do not need to be admitted to a radiotherapy room and outpatient treatment is possible. The radiation exposure from the patient is within the safety standards of the ICRP and IAEA recommendations for the general public and caregivers. Precautions for patients and their families, safety management associated with the use of [211At]NaAt, education and training, and disposal of medical radioactive contaminants are also included in this guideline. Treatment using [211At]NaAt in Japan should be carried out according to this guideline. Although this guideline is applied in Japan, the issues for radiation protection and evaluation methodology shown here are considered internationally useful as well.
Literature
1.
Release of patients who have been administered a radiopharmaceutical (Notification No. 0511–1 by the Director of Medical Care Planning Division, Health Policy Bureau, Ministry of Health, Labour and Welfare, dated May 11, 2016).
2.
Release of patients who have been administered a radiopharmaceutical (Notification No. 70 by the Director of the Safety Division, Pharmaceutical and Medical Safety Bureau, Ministry of Health, Labour and Welfare, dated June 30, 1998).
3.
Haugen BR, Alexander EK, Bible KC, et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26:1–133.CrossRef
4.
5.
ICRP Publication 53, Radiation dose to patients from radiopharmaceuticals. Ann ICRP 1988;18(1–4).
6.
ICRP Publication 60, Recommendations of the International Commission on Radiological Protection. Ann ICRP 1991;21(1–3).
7.
ICRP Publication 73, Radiological protection and safety in medicine. Ann ICRP 1996;26(2).
8.
ICRP Publication 94, Release of patients after therapy with unsealed radionuclides. Ann ICRP 2004;34(2).
9.
International basic safety standards for protection against ionizing radiation and for the safety of radiation sources, IAEA Safety Series, No. 115, 1996.
10.
Watabe T, Kaneda-Nakashima K, Liu Y, Shirakami Y, Ooe K, Toyoshima A, et al. Enhancement of 211At uptake via the sodium iodide symporter by the addition of ascorbic acid in targeted alpha therapy of thyroid cancer. J Nucl Med. 2019;60:1301–7.CrossRef
11.
Liu Y, Watabe T, Kaneda-Nakashima K, Ooe K, Shirakami Y, Toyoshima A, et al. Preclinical evaluation of radiation-induced toxicity in targeted alpha therapy using [211At] NaAt in mice: a revisit. Translational oncology. 2020;13:100757.CrossRef
12.
ICRP Publication 103. The recommendations of the International Commission on Radiological Protection. Ann ICRP. 2007;2007(37):2–4.
13.
14.
Koshida Y, Koga S, Orito T, Hiraki T, Takeuchi A, Nishizawa K, et al. Regarding the criteria for returning home and returning to general hospital room for 131I-treated patients based on external doses. Jpn J Nucl Med 1989:591–9.
15.
Sixth Study Group on the Ideal System for Providing Cancer Treatment — Document 5: Current Status of Nuclear Medicine Treatment (RI Internal Therapy, RI Treatment, Targeted Isotope Treatment)
16.
17.
K. Nishizawa, Ohara K, Ohshima M, Maekoshi H, Orito T, Watanabe T. Monitoring of I excretions and used materials of patients treated with 131I. Health Phys 1980;38:467.
18.
Manual on handling the diapers of patients who have been administered a radiopharmaceutical (Guidelines for medical personnel working in nuclear medicine) (March 2001, 1st ed., March 2004, 2nd ed.). Japanese Society of Nuclear Medicine, Japan Radiological Society, Japanese Society of Radiological Technology, Japanese Society of Nuclear Medicine Technology, and Japan Association on Radiological Protection in Medicine. http://​www.​jsnm.​org/​archives/​734/​.
19.
Act Regulating Radioactive Isotopes (Law No. 167, June 10, 1957)
20.
Medical Care Act (Law No. 205, July 30, 1948)
21.
Medical Care Act Implementing regulations (Ministry of Health, Labour and Welfare Ordinance No. 50, November 5, 1948)
22.
Ordinance on Prevention of Ionizing Radiation Hazards (Ministry of Health, Labour and Welfare Ordinance No. 41, September 30, 1972)
23.
Rules of the National Personnel Authority 10–5 (Prevention of radiation hazards for employees) (Rules of the National Personnel Authority 10–5, September 25, 1963)
24.
25.
Revised Medical Radiation Management Practice Manual, Japan Radioisotope Association, 2004.
Metadata
Title
Manual on the proper use of sodium astatide ([211At]NaAt) injections in clinical trials for targeted alpha therapy (1st edition)
Authors
Tadashi Watabe
Makoto Hosono
Seigo Kinuya
Takahiro Yamada
Sachiko Yanagida
Masao Namba
Yoshihide Nakamura
Publication date
01-07-2021
Publisher
Springer Singapore
Published in
Annals of Nuclear Medicine / Issue 7/2021
Print ISSN: 0914-7187
Electronic ISSN: 1864-6433
DOI
https://doi.org/10.1007/s12149-021-01619-2

Other articles of this Issue 7/2021

Annals of Nuclear Medicine 7/2021 Go to the issue

Original Article

Monte Carlo simulation of the acquisition conditions for 177Lu molecular imaging of hepatic tumors

Original Article

Therapeutic efficacy of 225Ac-PSMA-617 targeted alpha therapy in patients of metastatic castrate resistant prostate cancer after taxane-based chemotherapy

Original Article

Measuring myocardial blood flow with 82rubidium using Gjedde–Patlak–Rutland graphical analysis

Original Article

Prognostic value of 18F-FDG PET/CT with texture analysis in patients with rectal cancer treated by surgery

Review Article

The role of FDG PET/CT or PET/MRI in assessing response to neoadjuvant therapy for patients with borderline or resectable pancreatic cancer: a systematic literature review

Original Article

Effect of morphological findings in computed tomography on the quantitative values in single-photon emission computed tomography for patients with antiresorptive agent-related osteonecrosis of the jaw: a cross-sectional study